BALCHEM CORP
Close on Oct 19, 2026
- Market cap
- $5.49B
- P/E (TTM)
- 33.5
- Dividend yield
- 0.56%
Earnings
Next report expected Oct 20, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 31, 2026 | Before market open | $284.00M | $1.39 | $1.49 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $270.70M | $1.25 | $1.33 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 20, 2026 | Before market open | $263.60M | $1.21 | $1.31 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 21, 2025 | Before market open | $267.60M | $1.24 | $1.35 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $255.50M | $1.17 | $1.27 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | Before market open | $250.50M | $1.13 | $1.22 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 21, 2025 | Before market open | $240.00M | $1.03 | $1.13 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 25, 2024 | Before market open | $239.90M | $1.03 | $1.13 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 26, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 3, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 16, 2024 | Before market open | – | – | – |
Press releases
Announcements Balchem filed with the SEC
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Montvale, New Jersey. December 10, 2025 . Balchem
Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Montvale, New Jersey. December 10, 2024. Balchem
Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Montvale, New Jersey. December 5, 2023. Balchem
Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
payable on January 20, 2023 to stockholders of record at the close of business on December 27, 2022. This dividend represents an 10.9% increase over last year’s annual dividend.
Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health |
Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Balchem Corporation Completes Acquisition of Kappa Bioscience AS
Acquisition or disposition completed · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K
Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Results of operations · EX-99.1 to Form 8-K